# Chinese expert consensus on the diagnosis and treatment of plasmablastic lymphoma（2025）

## TL;DR

This paper presents a Chinese expert consensus on diagnosing and treating plasmablastic lymphoma, a rare and aggressive B-cell cancer.

## Contribution

The paper provides a consensus among Chinese experts to standardize diagnosis and treatment approaches for plasmablastic lymphoma.

## Key findings

- Plasmablastic lymphoma is a rare, aggressive B-cell lymphoma with distinct clinical and molecular features.
- Diagnosis and treatment of PBL remain challenging due to its low incidence and lack of standardized guidelines.
- The consensus aims to improve clinical recognition and facilitate multicenter research in China.

## Abstract

浆母细胞淋巴瘤（plasmablastic lymphoma，PBL）起源于生发中心终末分化期的活化B细胞，具有独特的临床、病理及分子学特征，呈现高度侵袭性、预后较差。PBL发病率低，诊断具有挑战性，治疗缺乏规范性。为加强我国临床医师对PBL的认识，提高诊断及治疗水平，有助于推动开展多中心临床研究，中华医学会血液学分会淋巴细胞疾病学组、中国临床肿瘤学会（CSCO）淋巴瘤专家委员会组织相关专家，讨论并形成本共识。